- Wang R, Gao Y, Lai L (2000) LigBuilder: a
multi-purpose program for structure-based
drug design. Mol Model Annu 6
(7–8):498–516 - de Kloe GE, Bailey D, Leurs R, de Esch IJ
(2009) Transforming fragments into candi-
dates: small becomes big in medicinal chemis-
try. Drug Discov Today 14(13):630–646 - Rees DC, Congreve M, Murray CW, Carr R
(2004) Fragment-based lead discovery. Nat
Rev Drug Discov 3(8):660–672 - Kumar A, Voet A, Zhang K (2012) Fragment
based drug design: from experimental to
computational approaches. Curr Med Chem
19(30):5128–5147 - Schro ̈dinger L (2013) Small-molecule drug
discovery suite 2013–3: QikProp, version 3.8.
Schro ̈dinger, LLC, New York - Schro ̈dinger Release (2014) 1: Desmond
molecular dynamics system, version 3.7. DE
Shaw Research, New York, NY, Maestro-
Desmond Interoperability Tools, version 3 - Schro ̈dinger Release (2013) 1: Schro ̈dinger
Suite 2013 Protein Preparation Wizard. Epik
version 2:2013
63. Schro ̈dinger L (2013) Small-molecule drug
discovery suite 2013–3: Glide, version 6.1.
Schro ̈dinger, LLC, New York
64. Pargellis C, Tong L, Churchill L, Cirillo PF,
Gilmore T, Graham AG, Grob PM, Hickey ER,
Moss N, Pav S (2002) Inhibition of p38 MAP
kinase by utilizing a novel allosteric binding
site. Nat Struct Mol Biol 9(4):268–272
65. Guarnieri F (2015) Designing a small molecule
erythropoietin mimetic. Methods Mol Biol
1289:185–210
66. Cohen SB, Cheng TT, Chindalore V,
Damjanov N, Burgos-Vargas R, DeLora P,
Zimany K, Travers H, Caulfield JP (2009)
Evaluation of the efficacy and safety of pamapi-
mod, a p38 MAP kinase inhibitor, in a double-
blind, methotrexate-controlled study of
patients with active rheumatoid arthritis.
Arthritis Rheumatol 60(2):335–344
67. Kandil S, Biondaro S, Vlachakis D, Cummins
A-C, Coluccia A, Berry C, Leyssen P, Neyts J,
Brancale A (2009) Discovery of a novel HCV
helicase inhibitor by a de novo drug design
approach. Bioorg Med Chem Lett 19
(11):2935–2937
144 Shashank P. Katiyar et al.